BMY vs BIIB — Key Metrics
| Metric | BMY (BRISTOL MYERS SQUIBB CO) | BIIB (BIOGEN INC) |
|---|---|---|
| Price | 62.4 | 225.88 |
| Market Cap | 127.47 Billion | 33.37 Billion |
| P/E (TTM) | 13.71 | 39.77 |
| P/B (Quarterly) | 5.936 | 1.64 |
| P/S (TTM) | 2.59 | 3.33 |
| Net Profit Margin (TTM) | 18.9 | 8.3 |
| Gross Margin (TTM) | 70.2 | 74.0 |
| ROE (TTM) | 46.8 | 4.5 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
BMY · BRISTOL MYERS SQUIBB CO
Outperform
BIIB · BIOGEN INC
Outperform
Recommendation Summary
Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: BMY.
Financial Metrics
Prices delayed ~15 min
| BMY | Metrics | BIIB |
|---|---|---|
| $62.40 | Price | $225.88 |
| — | Market Capitalization | — |
| 13.71 | Price to Earnings Ratio | 39.77 |
| 2.59 | Price to Sales | 3.33 |
| 11.14 | Price to FCF Ratio | 12.48 |
| 3.69 | Price to Gross Profit | 4.5 |
| 11.89 | Price to R&D | 16.57 |
| 4.46 | Price to Current Assets | 4.57 |